NYSEAMERICAN:ZOM Zomedica (ZOM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Zomedica Stock (NYSEAMERICAN:ZOM) Get Zomedica alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume790,936 shsAverage Volume4.72 million shsMarket Capitalization$95.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zomedica Corp. (NYSEAMERICAN:ZOM) is a veterinary health company focused on developing and commercializing products and services for companion-animal veterinarians. The company’s offerings are designed to support the diagnosis, treatment and monitoring of dogs, cats and other small animals in clinical settings. Zomedica’s product portfolio includes the Truforma point-of-care diagnostic platform, which uses immunoassay technology to help veterinary practices evaluate certain endocrine and adrenal conditions. The company also offers veterinary medical devices and therapeutic technologies, including PulseVet extracorporeal shock-wave therapy systems and products from Assisi Animal Health that use pulsed electromagnetic field technology. Founded in 2015, Zomedica has expanded its business through internal product development and acquisitions of veterinary technology companies. The company is headquartered in Ann Arbor, Michigan, and primarily serves the companion-animal veterinary market through direct and distribution-based sales channels. Its products are intended to help veterinary practices improve clinical decision-making and broaden the services available to pet owners.AI Generated. May Contain Errors. Read More Receive ZOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zomedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZOM Stock News HeadlinesZomedica Corp. (ZOMDF) Inside Marketing: How Demand Creation Drives Revenue and Supports Distinct Product Portfolios TranscriptSeptember 26, 2026 | seekingalpha.comZomedica stringe un accordo con un gruppo veterinario per i suoi prodottiSeptember 23, 2026 | it.investing.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 11 at 1:00 AM | Banyan Hill Publishing (Ad)Zomedica Corp. (ZOMDF) Q2 2026 Earnings Call TranscriptAugust 28, 2026 | seekingalpha.comZomedica Corp.: Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA PlatformAugust 13, 2026 | finanznachrichten.deZOMEDICA CORPJuly 30, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses Sales Strategy and Execution in Veterinary Medicine TranscriptJuly 25, 2026 | seekingalpha.comZomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on July 24, 2026: Zomedica's Sales Organization - From Strategy to the ClinicJuly 15, 2026 | finanznachrichten.deSee More Headlines ZOM Stock Analysis - Frequently Asked Questions How were Zomedica's earnings last quarter? Zomedica Corp. (NYSEAMERICAN:ZOM) announced its earnings results on Thursday, November, 7th. The company reported ($0.01) EPS for the quarter. The firm earned $7 million during the quarter. Zomedica had a negative trailing twelve-month return on equity of 12.47% and a negative net margin of 232.88%. Read the conference call transcript. How do I buy shares of Zomedica? Shares of ZOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica investors own include Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT), Phunware (PHUN) and Company Calendar Last Earnings11/07/2024Today10/11/2026Investor update10/23/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:ZOM CIK1684144 Webwww.zomedica.com Phone734-369-2555FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.53 million Net Margins-232.88% Pretax Margin-232.24% Return on Equity-12.47% Return on Assets-11.84% Debt Debt-to-Equity RatioN/A Current Ratio10.82 Quick Ratio10.15 Sales & Book Value Annual Sales$25.19 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / BookN/AMiscellaneous Outstanding Shares979,950,000Free Float938,890,000Market Cap$95.35 million OptionableNot Optionable Beta1.03 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NYSEAMERICAN:ZOM) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zomedica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
